Form 4: Bio-Techne Executive Boosts Equity Holdings

Sentiment:

Insider Transaction Report 19 August 2025 5:27 PM

Bio-Techne's President of Protein Sciences, William Geist, reported significant new equity grants and routine stock transactions.

Better than expectedThe filing indicates substantial new equity grants (19,355 performance restricted stock units, 9,678 restricted stock units, and 24,758 stock options) to a key executive, which is a positive sign of continued compensation and alignment with company performance.

Summary

William Geist, President of Protein Sciences at Bio-Techne Corp (TECH), reported multiple transactions on August 15, 2025.
Acquired 2,623 shares of common stock through the exercise of restricted stock units at a price of $0.
Disposed of 803 shares of common stock at a price of $53.6 per share, resulting in a net direct beneficial ownership of 15,112 common shares.
Received new grants of 19,355 performance restricted stock units, 9,678 restricted stock units, and 24,758 stock options with an exercise price of $53.6.

Sentiment

Score: 7

Explanation: The filing indicates significant new equity grants to a key executive, which is generally positive as it aligns management's interests with shareholder value creation. The disposition of shares is a routine tax-related event following RSU vesting.

Positives

Significant new grants of equity compensation, including 19,355 performance restricted stock units, 9,678 restricted stock units, and 24,758 stock options, align executive interests with long-term company performance.
The exercise of 2,623 restricted stock units at $0 indicates the vesting of previously granted equity, increasing the executive's direct share ownership before tax-related dispositions.

Negatives

Disposition of 803 shares of common stock, likely for tax withholding purposes, reduces the executive's direct beneficial ownership.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

The reported transactions are related party dealings as they involve an executive of Bio-Techne Corp acquiring and disposing of company securities.

Stakeholder Impact

Shareholders: The significant equity grants align the executive's financial interests with long-term shareholder value creation.
Employees: Reflects the company's compensation strategy for key personnel, potentially influencing broader compensation practices.

Next Steps

Future vesting of various stock options and restricted stock units on their respective scheduled dates, contingent on continued employment and, for performance units, achievement of specific performance goals.

Key Dates

Date	Description
02/01/2023	Vesting date for 3,980 stock options.
08/15/2023	Vesting date for 7,400 stock options.
02/01/2024	Vesting date for 3,976 stock options.
08/15/2024	Vesting date for 7,400 stock options and 7,515 stock options.
02/01/2025	Vesting date for 3,980 stock options.
08/15/2025	Transaction date for common stock acquisition and disposition, and new derivative security grants. Also a vesting date for 7,400 stock options, 7,515 stock options, 2,623 restricted stock units, and 5,301 stock options.
11/01/2025	Vesting date for 9,911 restricted stock units.
02/01/2026	Vesting date for 3,976 stock options.
08/15/2026	Vesting date for 7,400 stock options, 7,514 stock options, 2,623 restricted stock units, 5,301 stock options, 8,253 stock options, and potential vesting for performance restricted stock units and performance stock options if goals are achieved.
08/15/2027	Vesting date for 7,515 stock options, 2,623 restricted stock units, 5,301 stock options, 8,253 stock options, and potential vesting for performance restricted stock units if goals are achieved.
08/15/2028	Vesting date for 5,301 stock options, 8,252 stock options, and potential vesting for performance restricted stock units if goals are achieved.
02/01/2029	Expiration date for stock options with an exercise price of $100.39.
08/15/2029	Expiration date for stock options with an exercise price of $94.52.
08/15/2030	Expiration date for stock options with an exercise price of $84.61.
08/15/2034	Expiration date for stock options with an exercise price of $74.91.
08/15/2035	Expiration date for stock options with an exercise price of $53.6.
08/19/2025	Filing date of the Form 4.

Recommendation

hold

While the new equity grants are positive for aligning executive incentives, this Form 4 primarily details routine compensation and tax-related transactions rather than a strategic investment decision by the insider. It doesn't provide enough information to warrant a strong buy or sell recommendation, but the continued equity compensation structure supports a hold position for existing investors.

Keywords

Bio-Techne, TECH, Form 4, Insider Transaction, Executive Compensation, Stock Options, Restricted Stock Units, Equity Grants, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.